BioLineRx Ltd.
Monoclonal antibody and small molecule therapeutics for cancer and rare diseases
- Sector
- Biotech
- Headquarters
- MODI'IN, L3
- Latest Form D
- $3.8M, Sep 2026
- Total capital
- $17.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $17.1M
- 3 Form D · last Sep 2026
- 2 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 22 pending · first 2020
- Rank in peer group#122 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$3.8M
- Private capital raisedForm D · SEC · 2nd filing$4.4M
- Private capital raisedForm D · SEC · 1st filing$9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#122 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Abi A. Vainstein-HarasExecutive OfficerNamed in SEC Form D filings
- Aharon SchwartzDirectorNamed in SEC Form D filings
- Avraham Jean MolchoDirectorNamed in SEC Form D filings
- Barbara Jean BormannDirectorNamed in SEC Form D filings
- Ella A. SoraniExecutive OfficerNamed in SEC Form D filings
- Mali A. ZeeviExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Michael J. AnghelDirectorNamed in SEC Form D filings
- Nurit J. BenjaminiDirectorNamed in SEC Form D filings
- Philip A. SerlinExecutive OfficerNamed in SEC Form D filings
- Raphael Jean HofsteinDirectorNamed in SEC Form D filings
- Sandra Jean PanemDirectorNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 36- GrantedProcess For Manufacturing PeptideUSPTOUS 11,993,631
- GrantedCompositions And Methods For Treating CancerUSPTOUS 11,648,293
- GrantedCompositions And Methods For Treating CancerUSPTOUS 11,642,393
Show all 36 patent records
- Process For Manufacturing PeptideMay 28, 2024 · US 11,993,631Granted
- Compositions And Methods For Treating CancerMay 16, 2023 · US 11,648,293Granted
- Compositions And Methods For Treating CancerMay 9, 2023 · US 11,642,393Granted
- Compositions And Methods For Treating CancerMay 2, 2023 · US 11,638,742Granted
- Compositions And Methods For Treating CancerMay 2, 2023 · US 11,638,743Granted
- CXCR4 Inhibitor For The Treatment Of Acute Respiratory Distress Syndrome And Viral InfectionsApr 6, 2023 · Application 17910364Pending
- Compositions And Methods For Treating CancerMar 28, 2023 · US 11,612,638Granted
- Compositions And Methods For Treating CancerMar 21, 2023 · US 11,607,444Granted
- Compositions And Methods For Treating CancerMar 7, 2023 · US 11,596,666Granted
- Compositions And Methods For Treating CancerFeb 28, 2023 · US 11,590,200Granted
- Compositions And Methods For Treating CancerJan 24, 2023 · US 11,559,562Granted
- Compositions And Methods For Treating CancerJan 17, 2023 · US 11,554,159Granted
- Compositions And Methods For Treating CancerDec 27, 2022 · US 11,534,478Granted
- CXCR4 Inhibitor For The Treatment Of Acute Respiratory Distress Syndrome And Viral InfectionsSep 15, 2022 · Application 17827832Pending
- AGI-134 Combined With A Checkpoint Inhibitor For The Treatment Of Solid TumorsApr 29, 2021 · Application 17056803Pending
- Compositions, Articles Of Manufacture And Methods For Treating CancerDec 17, 2020 · Application 17006954Pending
- Compositions, Articles Of Manufacture And Methods For Treating CancerSep 29, 2020 · US 10,786,547Granted
- Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866627Pending
- Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866641Pending
- Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866615Pending
- Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866609Pending
- Compositions And Methods For Treating CancerSep 24, 2020 · Application 16866640Pending
- Compositions And Methods For Treating CancerSep 3, 2020 · Application 16866671Pending
- Compositions And Methods For Treating CancerAug 27, 2020 · Application 16866603Pending
- Compositions And Methods For Treating CancerAug 27, 2020 · Application 16866658Pending
- Compositions And Methods For Treating CancerJun 16, 2020 · US 10,682,390Granted
- Methods Of Treating Acute Myeloid Leukemia With A FLT3 MutationFeb 7, 2019 · Application 16163605Pending
- Methods Of Treating Myeloid LeukemiaDec 6, 2018 · Application 16049898Pending
- Methods Of Treating Myeloid LeukemiaNov 1, 2018 · Application 16035790Pending
- CXCR4 Binding Agents For Treatment Of DiseasesAug 9, 2018 · Application 15749558Pending
- Methods Of Obtaining Mononuclear Blood Cells And Uses ThereofJun 14, 2018 · Application 15571069Pending
- Methods Of Mesenchymal Stem Cell Mobilization And ExpansionMay 24, 2018 · Application 15570389Pending
- Methods Of Treating Acute Myeloid Leukemia With A FLT3 MutationAug 25, 2016 · Application 15027252Pending
- Methods Of Treating Myeloid LeukemiaMar 24, 2016 · Application 14771513Pending
- Crystalline Forms Of The Tri-mesylate Salt Of Perphenazine-gaba And Process Of Producing The SameJun 13, 2013 · Application 13763815Pending
- Methods Of Hematopoietic Precursor Cells MobilizationApplication 19469422Pending
Related companies, and why
- Therabene Inc.Similar federal contract value in Biotech · null in contracts
- Salve Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RHEUMAGEN, INC.Similar federal contract value in Biotech · null in contracts
- NANOPHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
- Nerio TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Zafrens Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .